|
Acute kidney injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Interleukin-20 induced cell death in renal epithelial cells and was associated with acute renal failure.
|
18496552 |
2008 |
|
Acute Kidney Insufficiency
|
0.300 |
Biomarker
|
disease |
CTD_human |
Interleukin-20 induced cell death in renal epithelial cells and was associated with acute renal failure.
|
18496552 |
2008 |
|
Adult Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In vitro, IL-20 expression increased in hypoxic HaCaT, HEK293 cells, chondrocytes, monocytes, and glioblastoma cells.
|
19342680 |
2009 |
|
Aggressive Periodontitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Extended haplotype analysis revealed an association of IL19/IL20 haplotype GACACCGGAA with a higher risk for PPP (OR 2 x 31, 95% CI 1 x 05-5 x 10) and of IL20/IL24 haplotype CAAAC with a reduced risk for PPP (OR 0 x 12, 95% CI 0 x 02-0 x 82).
|
17263806 |
2007 |
|
airway disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We concluded that genetic variation in adaptive immunity genes and particularly in IL19/IL20 genes associates with the development of recurrent wheeze after RSV LRTI, suggesting a role for these IL10 family members in the etiology of airway disease during infancy.
|
21814157 |
2011 |
|
Aortic Valve Insufficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
Accordingly, we also found a relative deficiency of antimicrobial proteins (AMPs) in AI lesions and a positive correlation between lesional IL-22 and IL-20 versus AMP levels.
|
21148041 |
2011 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
IL-20, an IL-10 family member, is involved in various inflammatory diseases, such as psoriasis, rheumatoid arthritis, and atherosclerosis.
|
19342680 |
2009 |
|
Arthritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Although mAbs against IL-19 and IL-20 have each been shown to modulate disease severity of collagen-induced arthritis in animal models, and anti-IL-20 therapeutic Ab has exhibited some efficacy in the treatment of RA in clinical trials, benefits for a complete blockade of these functionally redundant cytokines remain to be explored.
|
27619991 |
2016 |
|
Arthritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
In experimental models, anti-IL-20 monoclonal antibody ameliorates arthritis severity, protects against ovariectomized-induced bone loss, and inhibits breast tumor-induced osteolysis.
|
24816455 |
2014 |
|
Arthritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Thus, IL-20 may modulate the incidence and severity of arthritis and play important roles at local sites of inflammation.
|
16947773 |
2006 |
|
Arthritis, Psoriatic
|
0.010 |
Biomarker
|
disease |
BEFREE |
This review describes the IL-20 family of cytokines in rheumatoid arthritis (RA) and spondyloartrhitits (SpA) including psoriatic arthritis.
|
30319661 |
2018 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
LHGDN |
Therefore, we sought to investigate whether IL-20 is associated with atherosclerosis.
|
16778121 |
2006 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
IL-20, an IL-10 family member, is involved in various inflammatory diseases, such as psoriasis, rheumatoid arthritis, and atherosclerosis.
|
19342680 |
2009 |
|
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
In this review, we will discuss the immunobiological functions of IL-20R cytokines and how they are involved in regulating autoimmune diseases.
|
30260500 |
2018 |
|
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Furthermore, we demonstrate that the homodimeric IL-20R2 soluble receptor is a potent blocker for IL-24 and can be used to further dissect the crosstalk among the IL-20 family of cytokines in normal development as well as in autoimmune diseases.
|
20061404 |
2010 |
|
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases.
|
21073280 |
2011 |
|
Behcet Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
No statistically significant difference was detected between the IL-20 levels of the control group and the inactive BD patient group (p = 0.2).
|
30048054 |
2018 |
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study suggests the presence of specific inflammatory cytokine (IL-5, IL-20, and IL-28A)-mediated association in bladder cancer development.
|
22962576 |
2012 |
|
bone destruction
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, little is known about the role of IL-20 in bone destruction.
|
21844205 |
2011 |
|
Bone Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
This review article provides an overview describing the IL-20's biological functions in the common bone disorders and thus providing a novel therapeutic strategy in the future.
|
29690863 |
2018 |
|
Bone Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
IL-20 is emerging as a potent angiogenic, chemotactic, and proinflammatory cytokine related to several chronic inflammatory bone disorders likes intervertebral disc herniation, rheumatoid arthritis (RA), osteoporosis, and bone fracture.
|
30250404 |
2018 |
|
Brain Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Administration of IL-20 mAb ameliorated ischemia-induced brain infarction of rats after experimental ischemic stroke.
|
19342680 |
2009 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
IL-20 expression is regulated by a transcription elongation factor, Ell3, in estrogen receptor-positive (ER(+)) breast cancer cells.
|
28514748 |
2017 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Inhibition of IL-20 and KMT2B may have therapeutic benefits in ERα-positive breast cancer.
|
27806114 |
2016 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Recent evidence indicates that IL-20's interaction with its receptors might have proinflammatory effects on chronic inflammatory diseases, particularly rheumatoid arthritis (RA), osteoporosis, and breast cancer.
|
24816455 |
2014 |